ADC Therapeutics SA Price to Free Cash Flow Ratio 2019-2023 | ADCT
Historical price to free cash flow ratio values for ADC Therapeutics SA (ADCT) since 2019.
For more information on how our historical price data is adjusted see the Stock Price Adjustment Guide.
| ADC Therapeutics SA Price to Free Cash Flow Ratio Historical Data |
| Date |
Stock Price |
TTM FCF per Share |
Price to FCF Ratio |
| 2023-05-30 |
2.28 |
|
0.00 |
| 2023-03-31 |
1.95 |
$-1.51 |
0.00 |
| 2022-12-31 |
3.84 |
$-1.76 |
0.00 |
| 2022-09-30 |
4.82 |
$-1.89 |
0.00 |
| 2022-06-30 |
7.95 |
$-2.72 |
0.00 |
| 2022-03-31 |
14.69 |
$-2.80 |
0.00 |
| 2021-12-31 |
20.20 |
$-3.09 |
0.00 |
| 2021-09-30 |
27.16 |
$-3.21 |
0.00 |
| 2021-06-30 |
24.35 |
$-2.93 |
0.00 |
| 2021-03-31 |
24.41 |
$-3.32 |
0.00 |
| Sector |
Industry |
Market Cap |
Revenue |
| Medical |
Medical - Biomedical and Genetics |
$0.175B |
$0.210B |
|
ADC Therapeutics SA is a late clinical-stage oncology-focused biotechnology company. It engages in development and commercialization of antibody drug conjugates for patients suffering from hematological malignancies and solid tumors. ADC Therapeutics SA is based in LAUSANNE, Switzerland.
|
